Who are Ketanest®S's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Memantine (twice daily), Saline + Ketamine, Naloxone + Ketamine, S (+) Ketamine, Midazolam, ketamine, S-Ketamine 0.5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketanests.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ketanest®S — Competitive Intelligence Brief

Ketanest®S (Ketanest®S) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist; dissociative anesthetic. Area: Anesthesiology.

phase 3 NMDA receptor antagonist; dissociative anesthetic NMDA receptor (N-methyl-D-aspartate receptor) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Ketanest®S (Ketanest®S) — Chengdu Brilliant Pharmaceutical Co., Ltd.. Ketanest®S is a rapid-acting anesthetic that blocks NMDA receptors in the central nervous system to produce dissociative anesthesia and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ketanest®S TARGET	Ketanest®S	Chengdu Brilliant Pharmaceutical Co., Ltd.	phase 3	NMDA receptor antagonist; dissociative anesthetic	NMDA receptor (N-methyl-D-aspartate receptor)
Memantine (twice daily)	Memantine (twice daily)	H. Lundbeck A/S	marketed	NMDA receptor antagonist	NMDA receptor
Saline + Ketamine	Saline + Ketamine	Ullevaal University Hospital	marketed	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor (glutamate-gated ion channel)
Naloxone + Ketamine	Naloxone + Ketamine	Ullevaal University Hospital	marketed	Opioid antagonist + NMDA receptor antagonist combination	Opioid receptors (mu, delta, kappa) and NMDA receptor
S (+) Ketamine	S (+) Ketamine	Asker & Baerum Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Midazolam, ketamine	Midazolam, ketamine	Universidade Federal de Goias	marketed	Benzodiazepine + NMDA receptor antagonist combination	GABA-A receptor (midazolam); NMDA glutamate receptor (ketamine)
S-Ketamine 0.5	S-Ketamine 0.5	Turku University Hospital	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist; dissociative anesthetic class)

Chengdu Brilliant Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketanest®S — Competitive Intelligence Brief. https://druglandscape.com/ci/ketanests. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab